Moxifloxacin in the Treatment of Elderly Patients with Community-Acquired Pneumonia

• Mokdad AH , MarksJS, StroupDFet al.: Actual causes of death in the United States, 2000.JAMA291(10), 1238–1245(2004).
   PubMed Web of Science ®Google Scholar
• Ewig S , ReinertRR, WiedemannBet al.: Antibiotika-Resistenz bei Erregern ambulant erworbener Atemwegsinfektionen.Chemotherapie11, 12–26(2002).
   Google Scholar
• The British Thoracic Society: Guidelines for the management of community acquired pneumonia in adults admitted to hospital. Br. J. Hosp. Med.49, 346–350(1993).
   PubMed Web of Science ®Google Scholar
• Kaplan V , AngusDC, GriffinM, Clermont G, Scott WR, Linde-Zwirble WT: Hospitalized community-acquired pneumonia in the elderly: age-, sex-related patterns of care and outcome in the United States. Am. J. Respir. Crit. Care Med.165, 766–772(2002).
   PubMed Web of Science ®Google Scholar
• Guest JF , MorrisA: Community acquired pneumonia: the annual cost to the National Health Service in the UK.Eur. Respir. J.10, 1530–1534(1998).
   Web of Science ®Google Scholar
• Fry A , ShayD, HolmanRet al.: Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988–2002.JAMA294, 2712–2719(2005).
   PubMed Web of Science ®Google Scholar
• Meehan TP , FineMJ, KrumholzHMet al.: Quality of care, process, and outcomes in elderly patients with pneumonia.JAMA278, 2080–2084(1997).
   PubMed Web of Science ®Google Scholar
• Houck PM , BratzlerDW, NsaWet al.: Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia.Arch. Intern. Med.164, 637–644(2004).
   PubMedGoogle Scholar
• Lieberman D , SchlaefferF, BoldurIet al.: Multiple pathogens in adult patients admitted with community acquired pneumonia: a one year prospective study of 346 consecutive patients.Thorax51, 179–184(1996).
   PubMed Web of Science ®Google Scholar
• Zalacain R , TorresA, CelisRet al., on behalf of the Pneumonia in the elderly working group, Area de Tuberculosis e Infecciones Respiratorias: Community-acquired pneumonia in the elderly. Spanish multicentre study. Eur. Respir. J.21, 294–302(2003).
   PubMed Web of Science ®Google Scholar
• Fine MJ , AubleTE, YealyDMet al.: A prediction rule to identify low-risk patients with community-acquired pneumonia.N. Engl. J. Med.336, 243–250(1997).
   PubMed Web of Science ®Google Scholar
• El-Solh A , SikkaP, RamadanF, DaviesJ: Etiology of severe pneumonia in the very elderly.Am. J. Respir. Crit. Care Med.163, 645–651(2001).
   PubMed Web of Science ®Google Scholar
• Arancibia F , BauerT, EwigSet al.: Community-acquired pneumonia due to Gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis.Arch. Intern. Med.162, 1849–1858(2002).
   PubMed Web of Science ®Google Scholar
• Vandenesch F , EtienneJ: How to prevent transmission of MRSA in the open community?Euro. Surveill.9(11), 5 (2004).
   PubMedGoogle Scholar
• Miklaševics E , HæggmanS, BalodeAet al.: Report on the first PVL-positive community acquired MRSA strain in Latvia.Euro. Surveill.9(11), 29–30(2004).
   PubMedGoogle Scholar
• Wannet W , HeckM, PluisterG, SpalburgEet al.: Panton–Valentine leukocidin positive MRSA: the Dutch situation.Euro. Surveill.9(11), 28–29(2004).
   PubMedGoogle Scholar
• Fridkin SK , HagemanJC, MorrisonMet al.: Methicillin-resistant Staphylococcus aureus disease in three communities. N. Engl. J. Med.352, 1436–1444(2005).
   PubMed Web of Science ®Google Scholar
• Hageman JC , FrancisJ, UyekiTMet al.: Emergence of methicillin-resistant Staphylococcus aureus as a cause of community-acquired pneumonia during the influenza season, 2003–2004.Proceedings of the 42nd Annual Meeting of the Infectious Diseases Society of America. Infectious Diseases Society of America, Alexandria, VA, USA, 60 (2004) (Abstract LB-8).
   Google Scholar
• Breiman RF , ButlerJC, TenoverFCet al.: Emergence of drug-resistant pneumococcal infections in the United States.JAMA271, 1831–1835(1994).
   PubMed Web of Science ®Google Scholar
• Doern GV , BrueggemannA, HuynhHet al.: Antimicrobial resistance with Streptococcus pneumoniaein the United States, 1997–98. Emerg. Infect. Dis.5, 757–765(1999).
   PubMed Web of Science ®Google Scholar
• Ramsdell J , NarsavageG, FinkJ: Management of community-acquired pneumonia in the home: an American College of Chest Physicians clinical position statement.Chest127(5), 1752–1763(2005).
   PubMed Web of Science ®Google Scholar
• Patterson D : Collateral damage from cephalosporin or quinolone antibiotic therapy.Clin. Infect. Dis.38, S341–S345 (2004).
   PubMed Web of Science ®Google Scholar
• Marutani K , MatsumotoM, OtabeYet al.: Reduced phototoxicity of a fluoroquinolone antibacterial agent with a methoxy group at the 8 position in mice irradiated with long-wavelength UV light.Antimicrob. Agents Chemother.37, 2217–2223(1993).
   PubMed Web of Science ®Google Scholar
• Beyer R , PestovaE, MillichapJ, StosorV, NoskinG, PetersonL: A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin and trovafloxacin efflux.Antimicrob. Agents Chemother.44, 798–801(2000).
   PubMed Web of Science ®Google Scholar
• Ferrero L , CameronB, CrouzetJ: Analysis of gryA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus.Antimicrob. Agents Chemother.39, 1554–1558(1995).
   PubMed Web of Science ®Google Scholar
• Gootz TD , ZaniewskiR, HaskellSet al.: Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.Antimicrob. Agents Chemother.40, 2691–2697(1996).
   PubMed Web of Science ®Google Scholar
• Phillips S , Bararaman-PhillipsJ: The use of intramuscular cefoperazone versus intramuscular ceftriaxone in patients with nursing home acquired pneumonia.J. Am. Geriatr. Soc.4, 1071–1074(1993).
   Google Scholar
• Tanaka T , YoshikawaK, OriiYet al.: Interethnic difference in the pharmacokinetics of a novel quinolone antibiotic, BAY 12–8039 (moxifloxacin) and estimation of its clinical dose.Rinsho Yakuri30, 231–232(1999) (Abstract).
   Google Scholar
• Sullivan JT , WoodruffM, LettieriJet al.: Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12–8039), a new enantiomerically pure 8-methoxy quinolone.Antimicrob. Agents Chemother.43(11), 2793–2797(1999).
   PubMed Web of Science ®Google Scholar
• Stass H , DalhoffA, KubitzaDet al.: Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methy quinolone, administered to healthy subjects.Antimicrob. Agents Chemother.42(8), 2060–2065(1998).
   PubMed Web of Science ®Google Scholar
• Gotfried MH , DanzigerLH, RodvoldKA: Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects.Chest119, 1114–1122(2001).
   PubMed Web of Science ®Google Scholar
• Soman A , HoneybourneD, AndrewsJMet al.: Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fiberoptic bronchoscopy. J. Antimicrob. Chemother.44, 835–838(1999).
   PubMed Web of Science ®Google Scholar
• Woodcock J , AndrewsJ, BoswellF, BrenwaldN, WiseR: In-vitro activity of BAY 12–8039, a new fluoroquinolone.Antimicrob. Agents Chemother.41, 101–106(1997).
   PubMed Web of Science ®Google Scholar
• Andrews JM , Honeybourne,D, Brenwald NP et al.: Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fiber-optic bronchoscopy. J. Antimicrob. Chemother.39(6), 797–802(1997).
   PubMed Web of Science ®Google Scholar
• Doern GV , HeilmannKP, HuynhHKet al.: Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999–2000, including a comparison of resistance rates since 1994–1995. Antimicrob. Agents Chemother.45(6), 1721–1729(2001).
   PubMed Web of Science ®Google Scholar
• Jones ME , StaplesAM, CritchleyIet al.: Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States.Antimicrob. Agents Chemother.44(10), 2645–2652(2000).
   PubMed Web of Science ®Google Scholar
• Blondeau JM , LaskowskiR, BjarnasonJet al.: Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms. Int. J. Antimicrob. Agents14(1), 45–50(2000).
   PubMed Web of Science ®Google Scholar
• Noviello S , IannielloF, LeoneSet al.: Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.J. Antimicrob. Chemother.52(5), 869–872(2003).
   PubMed Web of Science ®Google Scholar
• Speciale A , MusumeciR, BlandinoGet al.: Minimal inhibitory concentrations and time-kill determination of moxifloxacin against aerobic and anaerobic isolates.Int. J. Antimicrob. Agents19(2), 111–118(2002).
   PubMed Web of Science ®Google Scholar
• Dorai-John T , ThomsonCJ, AmyesSG: Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom.J. Chemother.14(1), 19–24(2002).
   PubMed Web of Science ®Google Scholar
• Deshpande LM , JonesRN: Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999).Diagn. Microbiol. Infect. Dis.37(2), 139–142(2000).
   PubMed Web of Science ®Google Scholar
• Zhanel G , EnnisK, VercaigneLet al.: A critical review of FQs.Drugs62(1), 13–59(2002).
   PubMed Web of Science ®Google Scholar
• Roblin PM , ReznikT, KutlinAet al.: In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae.Antimicrob. Agents Chemother.43, 2806–2807(1999).
   PubMed Web of Science ®Google Scholar
• Duffy LB , KempfMC, CrabbDet al.: In vitro activity of moxifloxacin and six other new antimicrobials against Mycoplasma pneumoniae.39th Interscience Conference of Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, September 26–29 (1999).
   Google Scholar
• Schülin T , WennerstenCB, FerraroMJet al.: Susceptibilities of Legionella spp. to newer antimicrobials in vitro.Antimicrob. Agents Chemother.42, 1520–1523(1998) (Abstract 0367).
   PubMed Web of Science ®Google Scholar
• Dubois J , St-PierreC: In vitro activity of gatifloxacin, compared with ciprofloxacin, clarithromycin, erythromycin, and rifampin, against Legionella species.Diagn. Microbiol. Infect. Dis.33, 261–265(1999).
   PubMed Web of Science ®Google Scholar
• Goldstein E , CitronD, WarrenY, Tyrrell K, Merriam C, Fernandez H: In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections. Antimicrob. Agents Chemother.50, 148–155(2006).
   PubMed Web of Science ®Google Scholar
• Goldstein E , CitronD, HudspethM, GerardoS, MerriamC: In vitro activity of Bay 12–8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans.Antimicrob. Agents Chemother.41, 1552–1557(1997).
   PubMed Web of Science ®Google Scholar
• Ambrose P , GraselaD, GraselaT, Passarell J, Mayer H, Pierce P: Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob. Agents Chemother.45, 2793–2797(2001).
   PubMed Web of Science ®Google Scholar
• Lister P , SandersC: Pharmacodynamics of moxifloxacin, a review of worldwide post-marketing surveillance.J. Antimicrob. Chemother.47(6), 811–818(2001).
   PubMedGoogle Scholar
• Landen H , MollerM, TillotsonGSet al.: Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin.J. Int. Med. Res.29, 51–60(2001).
   PubMed Web of Science ®Google Scholar
• Visalli M , JacobsM, AppelbaumP: Antipneumococcal activity of BAY 12–8039, a new quinolone, compared with activities of three other quinolones and four oral β-lactams.Antimicrob. Agents Chemother.41(12), 2786–2789(1997).
   PubMed Web of Science ®Google Scholar
• Al-Nawas B , ShahPM: Intracellular activity of ciprofloxacin and moxifloxacin, a new 8-methoxyquinolone, against methicillin-resistant Staphylococcus aureus.J. Antimicrob. Chemother.41, 655–658(1998).
   PubMed Web of Science ®Google Scholar
• Li X , ZhaoX, DrlicaK: Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.Antimicrob. Agents Chemother.46(2), 522–524(2002).
   PubMed Web of Science ®Google Scholar
• Pestova E , BeyerR, NoskinGAet al.: Targeting of DNA gyrase by moxifloxacin, and effect of DNA gyrase and topoisomerase IV mutations on the activity of moxifloxacin against Streptococcus pneumoniae compared to other fluoroquinolone agents.99th General Meeting American Society for Microbiology, Chicago, IL, USA, 8 (1999) (Abstract A37).
   Google Scholar
• Barman Balfour J , Lamb H: Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs59, 115–139(2000).
   PubMed Web of Science ®Google Scholar
• Dalhoff A : Dissociated resistance among fluoroquinolones.Anti-Infect. Drug Chemother.16(Suppl. 1), 75–81(1998).
   Google Scholar
• Stass H , KubitzaD: Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man.J. Antimicrob. Chemother.43(Suppl. B), 83–90(1999).
   PubMed Web of Science ®Google Scholar
• Stass H , KubitzaD, WensingG: Pooled analysis of pharmacokinetics, safety and tolerability of single oral 400 mg moxifloxacin (MFX) doses in patients with mild and moderate liver cirrhosis (LC).40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada (2000) (Abstract 2269).
   Google Scholar
• Ittner K , RothG, GruberM, PawlikM, TaegerK: Clearance of moxifloxacin during continuous haemofiltration (CVVHF) in vitro.J. Antimicrob. Chemother.56, 360–364(2005).
   PubMed Web of Science ®Google Scholar
• Buxbaum A , StraschilU, MoserCet al.: Comparative susceptibility to penicillin and quinolones of 1385 Streptococcus pneumoniae isolates.J. Antimicrob. Chemother.43(Suppl. B), 13–18(1999).
   PubMed Web of Science ®Google Scholar
• Klugman K , CapperT: Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin.J. Antimicrob. Chemother.40, 797–802(1997).
   PubMed Web of Science ®Google Scholar
• Ednie L , JacobsM, AppelbaumP: Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms.Antimicrob. Agents Chemother.42, 2459–2462(1998).
   PubMed Web of Science ®Google Scholar
• Barry A , FuchsP, BrownS: Antibacterial activity of moxifloxacin (Bay 12–8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests.Eur. J. Clin. Microbiol. Infect. Dis.18, 305–309(1999).
   PubMed Web of Science ®Google Scholar
• Gosling R , UisoL, SamNet al.: The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis.Am. J. Respir. Crit. Care Med.168, 1342–1345(2003).
   PubMed Web of Science ®Google Scholar
• Gillespie S , GoslingR, UisoLet al.: Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis.J. Antimicrob. Chemother.56, 1169–1171(2005).
   PubMed Web of Science ®Google Scholar
• File T , LarsenL, FogartyCet al.: Safety and efficacy of sequential (IV to PO) moxifloxacin for the treatment of community-acquired pneumonia in hospitalized patients.Today‘s Ther. Trends19(4), 251–270(2001).
   Google Scholar
• Beecroft MD , Herman-GnjidicZ, Poulin-CostelloMet al.: Moxifloxacin in ambulatory pneumonia (MAP): clinical efficacy and safety of moxifloxacin in Canadian patients.Am. J. Respir. Crit. Care Med.165(8), A781 (2002) (Abstract).
   PubMedGoogle Scholar
• Fogarty C , GrossmanC, WilliamsJet al.: Efficacy and safety of cefuroxime axetil in the treatment of acute bacterial sinusitis in moxifloxacin vs clarithromycin for community-acquired pneumonia.Infect. Med.16(11), 748–763(1999).
   Google Scholar
• Hoeffken G , MeyerH, WinterJ, VerhoefL: The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia.Respir. Med.95(7), 553–564(2001).
   PubMed Web of Science ®Google Scholar
• Petitpretz P , ArvisP, MarelM, MoitaJ, UruetaJ: Oral moxifloxacin vs high- dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults.Chest119(1), 185–195(2001).
   PubMed Web of Science ®Google Scholar
• Torres A , MuirJF, CorrisPet al.: Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia.Eur. Respir. J.21(1), 135–143(2003).
   PubMed Web of Science ®Google Scholar
• Anzueto A , NiedermanM, PearleJ, RestrepoM, HeyderA, ChoudhriS, for the Community-Acquired Pneumonia Recovery in the Elderly Study Group: Community-Acquired Pneumonia Recovery In the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin. Infect. Dis.42, 73–81(2006).
   PubMed Web of Science ®Google Scholar
• Fogarty C , LarsenS, JacksonTet al.: Sequential intravenous to oral moxifloxacin monotherapy for community-acquired pneumonia.Pharmacotherapy22(10), 1349 (2002) (Abstract 147).
   Web of Science ®Google Scholar
• Finch R , SchurmannD, CollinsOet al.: Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.Antimicrob. Agents Chemother.46(6), 1746–1754(2002).
   PubMed Web of Science ®Google Scholar
• Choudhri S , HaverstockD, KruesmannF: Efficacy of po and iv moxifloxacin in the treatment of community-acquired pneumonia (CAP) in the very elderly (age >75 years).Program and abstracts of the 40th Annual Meeting of the Infectious Diseases Society of America, Infectious Diseases Society of America, Alexandria, VA, USA, 75 (2002) (Abstract 172).
   Google Scholar
• Landen H , MollerM, TillotsonGSet al.: Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin.J. Int. Med. Res.29, 51–60(2001).
   PubMed Web of Science ®Google Scholar
• Höffken G , MeyerHP, WinterJet al.: The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia.Respir. Med.95, 553–564(2001).
   PubMed Web of Science ®Google Scholar
• Petitpretz P , ArvisP, MarelMet al.: Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults.Chest119, 185–195(2001).
   PubMed Web of Science ®Google Scholar
• Torres A , ReadR, LodeHet al.: Once daily sequential intravenous/oral (IV/PO) moxifloxacin is equivalent to IV ceftriaxone plus twice daily IV/PO levofloxacin in the treatment of severe community-acquired pneumonia requiring hospitalization: the MOTIV study.6th European Congress of Clinical Microbiology and Infectious Diseases, Nice, France, April 1–4 (2006).
   Google Scholar
• Fogarty C , TorresA, ChoudhriSet al.: Moxifloxacin for treatment of penicillin-, macrolide-, and multi-drug resistant Streptococcus pneumoniae causing community-acquired pneumonia.Program and abstracts of the 44th Interscience Conference of Antimicrobial Agents and Chemotheraphy, Washington, DC, USA (2004).
   Google Scholar
• Drummond M , BeckerD, HuxMet al.: An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia.Chest124, 526–535(2003).
   PubMed Web of Science ®Google Scholar
• Church D , HaverstockD, HeydA: Moxifloxacin: a review of its safety profile based on worldwide clinical trials.American Society of Hispanic Psychiatry Annual Meeting, Philadelphia, PA, USA (2000).
   Google Scholar
• Hooper D , WolfsonJ: Adverse effects. In:Quinolone Antimicrobial Agents (2nd Edition). Hooper DC, Wolfson JS (Eds). Washington, DC, USA, 489–512(1993).
   Google Scholar
• Culley C , LacyM, KlutmanN, EdwardsB: Moxifloxacin: clinical efficacy and safety.Am. J. Health Syst. Pharm.58(5), 379–388(2001).
   PubMed Web of Science ®Google Scholar
• Morganroth J , DiMarcoJ, AnzuetoA, NiedermanM, ChoudhriS, theCAPRIE Study Group: A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest128, 3398–3406(2005).
   PubMed Web of Science ®Google Scholar
• Ball P : Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.J. Antimicrob. Chemother.45, 557–559(2000).
   PubMed Web of Science ®Google Scholar
• Lipsky BA , BakerCA: Fluoroquinolone toxicity profiles: a review focusing on newer agents.Clin. Infect. Dis.28, 352–364(1999).
   PubMed Web of Science ®Google Scholar
• Vohr H -W, Wasinska-Kempka G, Ahr HJ: Studies on the phototoxic potential of a new 8-methoxy-quinolone: BAY 12–8039. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, USA, 103 (1996) (Abstract F21).
   Google Scholar
• Matsumoto M , KojimaK, NaganoHet al.: Photostability and biological activity of fluoroquinolones substituted at the 8 position after UV irradiation.Antimicrob. Agents Chemother.36, 1715–1719(1992).
   PubMed Web of Science ®Google Scholar
• Stahlmann R , LodeH: Fluoroquinolones in the elderly.Drugs Aging20, 289–302(2003).
   PubMed Web of Science ®Google Scholar
• Simonin M -A, Gegout-Pottie P, Minn A et al.: Pefloxacin-induced achilles tendon toxicity in rodents: biochemical changes in proteoglycan synthesis and oxidative damage to collagen. Antimicrob. Agents Chemother.44, 867–872(2000).
   PubMed Web of Science ®Google Scholar
• Khaliq Y , ZhanelG: Fluoroquinolone-associated tendinopathy: a critical review of the literature.Clin. Infect. Dis.36, 1404–1410(2003).
   PubMed Web of Science ®Google Scholar
• Ackermann G , SchaumannR, PlessB, ClarosMC, GoldsteinEJ, RodloffAC: Comparative activity of moxifloxacin in vitro against obligate anaerobic bacteria.Eur. J. Clin. Microbiol. Infect. Dis.19, 228–232(2000).
   PubMed Web of Science ®Google Scholar
• Carroll DN : Moxifloxacin-induced Clostridium difficile-associated diarrhea.Pharmacotherapy23, 1517–1519(2003).
   PubMed Web of Science ®Google Scholar
• Ortiz-de-Saracho J , PantojaL, RomeroMJ, LopezR: Moxifloxacin-induced Clostridium difficile diarrhea.Ann. Pharmacother.37, 452–453(2003).
   PubMed Web of Science ®Google Scholar
• Ackermann G , Tang-FeldmanYJ, SchaumannRet al.: Antecedent use of fluoroquinolones is associated with resistance to moxifloxacin in Clostridium difficile.Clin. Microbiol. Infect.9, 526–530(2003).
   PubMed Web of Science ®Google Scholar
• Ackermann G , TangY, KueperRet al.: Resistance to moxifloxacin in toxigenic Clostridium difficileisolates is associated with mutations in gyrA.Antimicrob. Agents Chemother.45, 2348–2353(2001).
   PubMed Web of Science ®Google Scholar
• Stass H , KubitzaD: Profile of moxifloxacin drug interactions.Clin. Infect. Dis.32(Suppl. 1), S47–S50 (2001).
   PubMed Web of Science ®Google Scholar

Website

• Bayer Pharmaceuticals Corporation. AVELOX® (moxifloxacin hydrochloride) tablets and AVELOX® I.V. (moxifloxacin hydrochloride in sodium chloride injection): prescribing information www.bayerus.com
   Google Scholar